Olmesartan French Delisting Delayed, But Still Big Hit For Daiichi Sankyo
The antihypertensive olmesartan is to lose its reimbursement status in France next year, on the grounds that its efficacy had been shown to be less convincing that that of other angiotensin receptor blockers.
You may also be interested in...
A consultation on plans for the early availability of coronavirus vaccines drew almost 192,000 responses, including a number of concerns to which the government has now responded.
The health technology assessment bodies for England and Scotland have this week issued positive recommendations on the funding of several innovative new medicines on the National Health Service, including products for myeloma, kidney cancer and multiple sclerosis.
Proposals from NICE that are out for consultation are intended to boost the HTA body’s efficiency, improve transparency and governance, and raise the quality of its guidance.